Internists, Hematology Specialist, Oncology Specialist (cancer)
17 years of experience

Accepting new patients
Hematology Oncology Assoc
175 Madison Ave
Mount Holly, NJ 08060
Locations and availability (1)

Education ?

Medical School
University Of Cape Town (1993)
Foreign school

Awards & Distinctions ?

American Society of Hematology

Affiliations ?

Dr. Wallace is affiliated with 7 hospitals.

Hospital Affilations



  • St Barnabas Medical Center
    Medical Oncology
    94 Old Short Hills Rd, Livingston, NJ 07039
    • Currently 3 of 4 crosses
    Top 50%
  • Virtua West Jersey Hospital - Marlton
    Medical Oncology
    94 Brick Rd, Marlton, NJ 08053
    • Currently 2 of 4 crosses
  • Virtua Memorial Hospital Of Burlington County
    Medical Oncology
    175 Madison Ave, Mount Holly, NJ 08060
    • Currently 2 of 4 crosses
  • Virtua West Jersey Hospital - Voorhees
    94 Brick Rd, Marlton, NJ 08053
    • Currently 2 of 4 crosses
  • Fox Chase Virtua CancerProgram
  • Fox Chase Cancer Center
  • Virtua West Jersey Health System-Voorh
  • Publications & Research

    Dr. Wallace has contributed to 1 publication.
    Title Factors Associated with Toxicity and Response to Yttrium 90-labeled Ibritumomab Tiuxetan in Patients with Indolent Non-hodgkin's Lymphoma.
    Date February 2005
    Journal Clinical Lymphoma

    Treatment of patients with indolent non-Hodgkin's lymphoma (NHL) is evolving. These patients usually present with advanced-stage disease. Treatment options for patients who experience relapse are limited, and no treatment has been shown to be superior to others in improving overall survival of this group of patients, with the possible exception of allogeneic stem cell transplantation. Therefore, new approaches are needed to improve outcomes in patients with relapsed or refractory disease. The anti-CD20 monoclonal antibody, rituximab, was the first monoclonal antibody approved for the treatment of indolent B-cell NHL. As a single agent in the treatment of relapsed or refractory indolent lymphoma, response rates as high as 56% have been observed. This promising new therapy was followed by development of radioimmunotherapy, a novel treatment approach that combines the targeting capability of monoclonal antibodies with the additional cytotoxic effects of radiation. Yttrium 90-labeled ibritumomab tiuxetan (Zevalin) is a radiolabeled monoclonal antibody that has been shown to produce clinically significant responses in up to 80% of patients with indolent NHL and is the first radiolabeled monoclonal antibody approved for therapeutic use in the treatment of lymphoma. This article reviews some of the safety and efficacy data for this agent in addition to examining factors that could aid in predicting response and toxicity in patients with low-grade relapsed or refractory NHL treated with 90Y ibritumomab tiuxetan.

    Similar doctors nearby

    Dr. Michael Kleinman

    General Practice
    11 years experience
    Marlton, NJ

    Dr. Nancy Ruiz

    Internal Medicine
    27 years experience
    Feasterville Trevose, PA

    Dr. Michael Ciencewicki

    Internal Medicine
    34 years experience
    Marlboro, NJ

    Dr. Nicholas Wilson

    Internal Medicine
    Philadelphia, PA

    Dr. Noor Ahmad

    Internal Medicine
    Philadelphia, PA

    Dr. Vikranta Sharma

    Internal Medicine
    16 years experience
    Monroe Township, NJ
    Search All Similar Doctors